Format

Send to

Choose Destination
Rev Prat. 2018 Jan;68(1):18-24.

[Management of functional bowel disorders].

[Article in French; Abstract available in French from the publisher]

Author information

1
Service d'hépato-gastroentérologie et de nutrition, UMR 1073, hôpital Charles-Nicolle, Rouen, France.

Abstract

in English, French

Management of functional bowel disorders. The better knowledge of irritable bowel syndrome (IBS) and functional bloating pathogenic mechanisms led to an increase of the possible therapeutic options, which are somewhat different, in IBS, between IBS-D and IBS-C Besides routine options (antispasmodics, alverine, laxatives, loperamide), low-dose antidepressants and non-pharmaceutical options are now recognized as validated and effective therapeutic choices. In addition, dietary advices (particularly indication of a low FODMAPs diet) and treatments acting on gut microbiota (probiotics, antibiotics) are more and more discussed and indicated. In functional bloating, treatment remains empirical. Dietary modifications, simeticone, prokinetics, low-dose antidepressants and microbiome modulation can be proposed.

KEYWORDS:

colonic diseases, functional; therapeutics

PMID:
30840380

Conflict of interest statement

P. Ducrotté a effectué des interventions ponctuelles de conseil scientifique pour Allergan, Almirall, Danone, Ipsen-Pharma et Mayoly-Spindler, a joué le rôle d’investigateur principal dans des essais cliniques promus par Ipsen-Pharma, Mayoly-Spindler et Teva-Santé et a assuré des conférences sur invitation en qualité d’intervenant pour Allergan, Almirall, Biocodex, Boehringer-Ingelheim, Ipsen-Pharma, Mayoly-Spindler, et Teva-Santé. C. Melchior déclare n’avoir aucun lien d’intérêts.

Supplemental Content

Loading ...
Support Center